Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. - Wikidata - wikimedia - TriplyDB

Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.

Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.

http://www.wikidata.org/entity/Q35265686

about

Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal: A Review of the Preclinical Animal Literature Medications development for opioid abuse Chemical probes of endocannabinoid metabolism Therapeutic potential of monoacylglycerol lipase inhibitors Monoacylglycerol lipase - a target for drug development?AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.Mice expressing a "hyper-sensitive" form of the CB1 cannabinoid receptor (CB1) show modestly enhanced alcohol preference and consumption.Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell.Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.Inhibition of monoacylglycerol lipase reduces nicotine withdrawal Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies.Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation.Production and actions of the anandamide metabolite prostamide E2 in the renal medulla Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex.Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.Double Dissociation of Monoacylglycerol Lipase Inhibition and CB1 Antagonism in the Central Amygdala, Basolateral Amygdala, and the Interoceptive Insular Cortex on the Affective Properties of Acute Naloxone-Precipitated Morphine Withdrawal in Rats Endocannabinoid and cannabinoid-like fatty acid amide levels correlate with pain-related symptoms in patients with IBS-D and IBS-C: a pilot study.In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects.Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids.Using dopamine research to generate rational cannabinoid drug policy.Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone?Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors.Experiences of Kratom Users: A Qualitative Analysis.Monoglyceride lipase as a drug target: At the crossroads of arachidonic acid metabolism and endocannabinoid signaling.Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice.Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms.CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors.

P2860

Q26738333-A539F2BC-5157-41E6-AC3F-F0B023EB1234 Q26853370-E42DDE0B-B2A4-462C-A2D7-5402828BE41A Q26863202-C98751C8-035E-4273-B52D-868C2B79924C Q26991513-DCC29B56-E56A-4250-8968-52C485565005 Q26998964-C1F89DEF-E0A3-4575-AADE-6CDF5CA61E54 Q28270589-9E07AA1F-035B-4A38-8C5B-B6AB234BF090 Q28283718-4B0B4A93-5C80-4D05-BA6B-21229C5B324B Q28300390-97E4CBA6-0769-43B0-B196-FAD7AEA3F58F Q30733453-D67615CC-7685-4E6F-BC16-9CAFF87596F3 Q33585822-43F77B08-4EF1-42B2-872B-DECF4CEA1D80 Q34156640-E3B4CF6B-1B84-4361-9F1C-EB83F491401D Q34219132-675F0A83-A255-426C-BC98-5A5782B761DE Q34359778-D8474D99-A787-4CD8-8C40-FF8499DD274A Q34973799-5F239F7B-8EF8-45E7-9CB4-40F6E690A603 Q34994542-05749A4E-F486-42F4-A62E-A117C7915E51 Q35053193-B373176E-E387-48BF-AF1F-84F7F7E205E9 Q35531804-56349C04-7336-45F4-A24B-495AAE0D9A2B Q35693020-7B2730DE-60FB-4C51-B48C-B0C2C80F2C77 Q36174214-F6D5FFA1-2466-4C7B-BC00-9DBD24C52B2F Q36421863-82749654-A2FF-457B-8605-F6FB5F7A604E Q36429054-CDD67BFA-9A91-4EAF-891A-54DC9074BA6B Q36775254-A2E35420-F95B-4FEC-B4FB-8096C11FC7E5 Q36906676-D3BCC947-5A42-463B-BA6C-010795AD3A32 Q37416662-E7A30938-1210-4CD3-B26D-9AB4C3A1E2A0 Q37637750-7065CF6F-E0BE-4C22-B6E2-DE218D8AA189 Q38026790-E2992BD5-A830-47DB-A0F7-94B8AAA49E92 Q38044684-469AF734-E86F-47DF-94F9-12C2C36D38BB Q38126265-C912B7B8-F391-444A-A93E-0D674DC0309B Q38212376-02CDF011-3B06-4EFA-A9CF-CB45DA1AB596 Q38636791-B32C215B-02B5-42BD-A4C8-CDA4E87EABB1 Q38911009-C46011FF-0A79-40AF-9D2A-5F421108CED6 Q38940009-77D86CF7-B9D5-4EE1-A362-A9C39835EC5A Q39141240-BDAC49F1-5212-4775-8643-89625DF5EA51 Q41810036-E9A780C1-68F6-45B4-8689-54162FA61D47 Q42407000-D36C8C17-763E-4B17-9B4C-BB9197D4C787 Q42700473-A85C598C-7A70-4EEB-B590-35AD4B85647A Q42961232-7D9C2A03-32E3-4933-9606-2F9E58C3C715 Q44332602-60E86A94-01DB-429B-A401-C220FCC36DB1 Q45047828-5E86ABF1-6232-48AA-8AFE-BABB1D6BACF3 Q47763157-C9A1B70F-F16B-4A2E-AD63-C3CCF7C91D79

P2860

Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.

http://www.wikidata.org/entity/Q35265686

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@ast

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@en

type

label

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@ast

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@en

prefLabel

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@ast

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@en

P1433

Q35265686-DE88B152-7B65-4942-918B-6386DB2FAF59

P1476

Q35265686-CC2D71EE-DB1B-477D-887D-A170B87D2A95

P2093

Q35265686-06190807-77E9-46D0-9640-E3BAD30A2CC2

Q35265686-18E8E30C-8B05-40E3-BFB3-3498E65D769E

Q35265686-3B57468A-469E-4A25-A81E-3019C083DE88

Q35265686-3B68A4CD-12EE-4B6D-B9C0-E14DFA1820D5

Q35265686-9255079D-7125-4E61-A0D7-E87F3FDF046F

Q35265686-96E7024E-F446-4431-91CF-33311DC5B473

Q35265686-BA0CF9E9-7453-4930-8B6C-6E7BEED1631D

Q35265686-C55DB727-4C9C-4CD3-86D5-782AB8A18B95

Q35265686-D0BFBCCD-7A83-4CF5-BB11-20C8BC4C5670

Q35265686-D795B212-8D6D-41A5-9C15-467CF29A1603

P2860

Q35265686-082CCB5B-F4AC-447A-88E4-A85419086990

Q35265686-0A82A719-1851-4706-905A-DCA979B0FC6F

Q35265686-0BB5D720-A543-4D1E-94B7-FB502CB83794

Q35265686-0BFB229E-83AA-4DBC-B2CB-E45266556FE3

Q35265686-16E1765A-CCE4-4CCA-990E-807276B565F2

Q35265686-1A9AB211-1B7C-44AD-A121-B3E3D26B949F

Q35265686-1C81BAA4-7617-46F6-8291-E5D4FE342E48

Q35265686-3183F15D-B379-41E7-AF0A-27153936F8F4

Q35265686-36262E60-0E52-4355-B770-93A27198B775

Q35265686-379FCA35-D5EC-4CC5-B408-E01965345D9A

P304

Q35265686-3C32E0A6-C686-4025-B746-587C406CB398

P31

Q35265686-0152B159-A981-4DFC-8C07-0F2FCF5DE13B

P356

Q35265686-47A8B936-5B4F-480B-92EC-97FE22716297

P407

Q35265686-8A0D39D5-066E-4B40-A69C-AE2AF6B0F646

P433

Q35265686-BBADCC40-3662-4303-AF46-44C22E93630F

P478

Q35265686-5AD9104F-9086-418A-8C6A-3C3B44BE2318

P50

Q35265686-04064A5F-EE6A-4745-A8ED-8CEF3B445F7E

Q35265686-C6A7B20F-0A78-44B3-9249-B662783563DE

P577

Q35265686-00FA2B6D-2250-4AB0-BE9E-8E5E630D967B

P5875

Q35265686-6FD989EE-9E1B-4866-A61B-0D314D8C0A4A

P698

Q35265686-DBF22E0C-312F-4B7B-B6F3-C1BF347B369F

P921

Q35265686-FC09DCE7-5E1D-49AA-8977-3D7FA351A3BE

P932

Q35265686-13975752-3FE9-46EB-B0F4-D7BBFA4A460D

P356

JPET.111.181370

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Blockade of endocannabinoid hy ...... d withdrawal symptoms in mice.

@en

P2093

Aron H Lichtman

http://www.w3.org/2001/XMLSchema#string

Daniel K Nomura

http://www.w3.org/2001/XMLSchema#string

Divya Ramesh

http://www.w3.org/2001/XMLSchema#string

Gracious R Ross

http://www.w3.org/2001/XMLSchema#string

Joel E Schlosburg

http://www.w3.org/2001/XMLSchema#string

Jonathan Z Long

http://www.w3.org/2001/XMLSchema#string

Laura J Sim-Selley

http://www.w3.org/2001/XMLSchema#string

Rehab A Abdullah

http://www.w3.org/2001/XMLSchema#string

Robert A Owens

http://www.w3.org/2001/XMLSchema#string

Steven G Kinsey

http://www.w3.org/2001/XMLSchema#string

P2860

Brain monoglyceride lipase participating in endocannabinoid inactivation

Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase

Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects

The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors

Discovery and Characterization of a Highly Selective FAAH Inhibitor that Reduces Inflammatory Pain

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain

Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors

Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides

Molecular characterization of a peripheral receptor for cannabinoids

P304

173-185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1124/JPET.111.181370

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

339

http://www.w3.org/2001/XMLSchema#string

P50

Hamid I. Akbarali

Benjamin Cravatt III

P577

2011-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51457962

http://www.w3.org/2001/XMLSchema#string

P698

21719468

http://www.w3.org/2001/XMLSchema#string

P921

endocannabinoids

P932

3186294

http://www.w3.org/2001/XMLSchema#string